Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)
|
March 16, 2001
ZD-0473 AstraZeneca
M P Hay
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 12, 2019
Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs
R K Jackson, L P Liew, M P Hay
The British Journal of Cancer. Supplement
|
July 1, 1996
Recent developments in the design of bioreductive drugs
W A Denny, W R Wilson, M P Hay
Bioorganic & Medicinal Chemistry Letters
|
January 5, 2000
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT)
M P Hay, W R Wilson, W A Denny
Anti-Cancer Drug Design
|
July 1, 1996
Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins
M P Hay, W A Denny, W R Wilson
The British Journal of Cancer. Supplement
|
July 1, 1996
Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1
R M Batchelder, W R Wilson, M P Hay, et al.
Cancer Research
|
February 1, 1995
N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug
J W Moselen, M P Hay, W A Denny, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 28, 1999
A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT
M P Hay, B M Sykes, W A Denny, et al.
Anti-Cancer Drug Design
|
September 29, 1999
Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA)
A Haldane, G J Finlay, M P Hay, et al.
Journal of Medicinal Chemistry
|
May 26, 1995
Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility
M P Hay, H H Lee, W R Wilson, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Current Opinion in Investigational Drugs (London, England : 2000)
|
March 16, 2001
ZD-0473 AstraZeneca
M P Hay
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 12, 2019
Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs
R K Jackson, L P Liew, M P Hay
The British Journal of Cancer. Supplement
|
July 1, 1996
Recent developments in the design of bioreductive drugs
W A Denny, W R Wilson, M P Hay
Bioorganic & Medicinal Chemistry Letters
|
January 5, 2000
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT)
M P Hay, W R Wilson, W A Denny
Anti-Cancer Drug Design
|
July 1, 1996
Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins
M P Hay, W A Denny, W R Wilson
The British Journal of Cancer. Supplement
|
July 1, 1996
Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1
R M Batchelder, W R Wilson, M P Hay, et al.
Cancer Research
|
February 1, 1995
N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug
J W Moselen, M P Hay, W A Denny, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 28, 1999
A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT
M P Hay, B M Sykes, W A Denny, et al.
Anti-Cancer Drug Design
|
September 29, 1999
Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA)
A Haldane, G J Finlay, M P Hay, et al.
Journal of Medicinal Chemistry
|
May 26, 1995
Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility
M P Hay, H H Lee, W R Wilson, et al.
Page
of 2